BMS

Showing 15 posts of 285 posts found.

shutterstock_179291957

CHMP issues positive opinion for Orencia Rheumatoid Arthritis treatment

July 25, 2016
Manufacturing and Production, Sales and Marketing BMS, CHMP, Orencia, rheumatoid arthritis

Bristol-Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion of …

Bristol-Myers Squibb settle $30 million California kickback lawsuit

July 20, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, california, lawsuit

Bristol-Myers Squibb (BMS) has agreed to pay $30 million to the California Department of Insurance to settle an almost decade …

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals in deal worth up to $425 million

July 6, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, cormorant

Bristol-Myers Squibb (NYSE: BMY) has announced that it has acquired all outstanding capital stock of Sweden-based Cormorant Pharmaceuticals, granting it …

Murdo Gordon gets Chief Commercial Officer role at Bristol-Myers Squibb

June 21, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, chief commercial officer

Bristol-Myers Squibb (NYSE: BMY) has announced the appointment of Munro Gordon as executive vice president and chief commercial officer, effective …

Nice backs BMS’ combination immunotherapy Opdivo, Yervoy to treat skin cancer

June 17, 2016
Medical Communications, Research and Development, Sales and Marketing BMS, NICE, oncology, opdivo, regulation, skin cancer

The National Institute for Health and Care Excellence (Nice) has backed a combination of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) and …

Nice recommends three drugs to treat diabetes

May 25, 2016
Research and Development, Sales and Marketing AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, NICE, diabetes

The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …

Multiple myeloma treatment from BMS and AbbVie scores EU approval

May 12, 2016
Research and Development, Sales and Marketing AbbVie, BMS, EMA, EU, Empliciti, approval, bristl-myers squibb, elotuzumab, multiple myeloma

Bristol-Myers Squibb (NYSE: BMY) and AbbVie (NYSE: ABBV) have announced that the European Commission has approved Empliciti (elotuzumab) for the …

NICE backs BMS’ paclitaxel in ovarian cancer; drops Eli Lilly’s Gemzar, J&J’s Yondelis

April 27, 2016
Research and Development, Sales and Marketing BMS, Eli Lilly, J&J, JJ, NICE, ovarian cancer, regulation

The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …

opdivo_1_1

Focus: Bristol-Myers Squibb’s wonder drug – Opdivo

April 20, 2016
Research and Development, Sales and Marketing BMS, growth, immuno-oncology, opdivo, sales

By Anjali ShuklaNew data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat head and neck cancer showed superior survival compared with …

Empliciti pack shot

EMA fast-tracks BMS multiple myeloma drug

February 1, 2016
Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, EMA, Empliciti, myeloma

The EMA has recommended granting a marketing authorisation for Bristol Myers-Squibb and AbbVie’s immunotherapy Empliciti for the treatment of multiple myeloma. The …

FDA building

FDA approves new uses for BMS’ Opdivo/Yervoy cancer combo

January 25, 2016
Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilimumabm melanoma, nivolumab, opdivo, skin cancer

The FDA has granted Bristol Myers Squibb an expanded indication for its two-cancer drug regimen Opdivo and Yervoy, to treat …

Opdivo

NICE ‘yes’ for BMS skin cancer drug Opdivo

January 22, 2016
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, melanoma, nivolumab, opdivo, skin cancer

NICE has approved Bristol-Myers Squibb’s skin cancer immunotherapy Opdivo (nivolumab) in final draft guidance as monotherapy for NHS patients in England …

landing-hero-images1

ViiV Healthcare to acquire Bristol-Myers Squibb’s HIV pipeline drugs

December 18, 2015
Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, HIV, ViiV, ViiV Healthcare

Specialist HIV company ViiV Healthcare has agreed deals worth up to $1.46 billion to purchase Bristol-Myers Squibb’s late stage HIV …

NHS sign

NICE rejects BMS cancer drug in draft guidance

December 16, 2015
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …

Bristol-Myers Squibb chooses UCLA as latest research partner

December 14, 2015
Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, University of California Los Angeles, rare malignancies, ucla

Pharma firm Bristol-Myers Squibb is entered into a new collaboration agreement with the University of California Los Angeles (UCLA) as …

Latest content